Bergmann Carsten
Center for Human Genetics, Bioscientia, Ingelheim, Germany.
Department of Medicine, University Hospital Freiburg, Freiburg, Germany.
Front Pediatr. 2018 Feb 9;5:221. doi: 10.3389/fped.2017.00221. eCollection 2017.
Autosomal recessive polycystic kidney disease (ARPKD) is a hepatorenal fibrocystic disorder that is characterized by enlarged kidneys with progressive loss of renal function and biliary duct dilatation and congenital hepatic fibrosis that leads to portal hypertension in some patients. Mutations in the gene are the primary cause of ARPKD; however, the disease is genetically not as homogeneous as long thought and mutations in several other cystogenes can phenocopy ARPKD. The family history usually is negative, both for recessive, but also often for dominant disease genes due to arisen mutations or recessive inheritance of variants in genes that usually follow dominant patterns such as the main ADPKD genes and . Considerable progress has been made in the understanding of polycystic kidney disease (PKD). A reduced dosage of disease proteins leads to the disruption of signaling pathways underlying key mechanisms involved in cellular homeostasis, which may help to explain the accelerated and severe clinical progression of disease course in some PKD patients. A comprehensive knowledge of disease-causing genes is essential for counseling and to avoid genetic misdiagnosis, which is particularly important in the prenatal setting (e.g., preimplantation genetic diagnosis/PGD). For ARPKD, there is a strong demand for early and reliable prenatal diagnosis, which is only feasible by molecular genetic analysis. A clear genetic diagnosis is helpful for many families and improves the clinical management of patients. Unnecessary and invasive measures can be avoided and renal and extrarenal comorbidities early be detected in the clinical course. The increasing number of genes that have to be considered benefit from the advances of next-generation sequencing (NGS) which allows simultaneous analysis of a large group of genes in a single test at relatively low cost and has become the mainstay for genetic diagnosis. The broad phenotypic and genetic heterogeneity of cystic and polycystic kidney diseases make NGS a particularly powerful approach for these indications. Interpretation of genetic data becomes the challenge and requires deep clinical understanding.
常染色体隐性多囊肾病(ARPKD)是一种肝肾纤维囊性疾病,其特征为肾脏增大,肾功能进行性丧失,胆管扩张,以及先天性肝纤维化,部分患者会由此导致门静脉高压。该基因的突变是ARPKD的主要病因;然而,该病在遗传上并不像长期以来认为的那样具有同质性,其他几个囊肿基因的突变也可表现出与ARPKD相似的表型。家族史通常呈阴性,对于隐性疾病基因如此,对于显性疾病基因也常常如此,这是由于出现了新发突变,或者通常遵循显性模式的基因(如主要的常染色体显性多囊肾病基因PKD1和PKD2)中的变异发生了隐性遗传。在多囊肾病(PKD)的认识方面已经取得了相当大的进展。疾病蛋白剂量的减少会导致细胞内稳态关键机制所涉及的信号通路中断,这可能有助于解释一些PKD患者疾病进程加速和临床症状严重的原因。全面了解致病基因对于遗传咨询和避免基因误诊至关重要,这在产前诊断(如植入前基因诊断/PGD)中尤为重要。对于ARPKD,强烈需要早期且可靠的产前诊断,而这只有通过分子遗传学分析才可行。明确的基因诊断对许多家庭有帮助,并能改善患者的临床管理。可以避免不必要的侵入性措施,并在临床过程中早期检测出肾脏和肾外合并症。由于下一代测序(NGS)技术的进步,需要考虑的基因数量不断增加,NGS能够以相对较低的成本在一次检测中同时分析一大组基因,已成为基因诊断的主要手段。囊性和多囊性肾病广泛的表型和遗传异质性使得NGS成为针对这些病症的一种特别有效的方法。遗传数据的解读成为一项挑战,需要深入的临床理解。